How Mounjaro and Zepbound work — mechanism comparison
Mounjaro and Zepbound contain the same active ingredient (tirzepatide), so they work through the same molecular pathway. The differences are in dosing, FDA-approved indications, and labeling — not in how the drug acts on your body. Both bind to GLP-1 receptors, slow gastric emptying, increase insulin secretion in response to meals, and signal satiety to the brain.
This shared mechanism matters because it determines: efficacy (how much weight loss / blood-sugar control you can expect), side-effect profile, dosing schedule, and which patients may benefit most. Read more in our Mounjaro mechanism guide and Zepbound mechanism guide.
Efficacy head-to-head
In their respective pivotal trials, mean body-weight reduction reached:
- Mounjaro: no weight-loss trial of its own
- Zepbound: 22.5% at 72 weeks (trial: SURMOUNT-1)
Side-by-side radar: Mounjaro vs Zepbound
Editorial scoring across 5 dimensions, overlaid. Higher area = better overall fit.
| Axis | Mounjaro | Zepbound |
|---|---|---|
| Efficacy | 10 | 10 |
| Convenience | 9 | 9 |
| Affordability | 5 | 5 |
| Tolerance | 6 | 6 |
| Evidence | 6 | 6 |
Higher score = better on that axis. Editorial scoring; not a substitute for prescriber judgment.
Side effects compared
Both drugs share the GLP-1 class side-effect profile — primarily gastrointestinal (nausea, diarrhea, constipation, vomiting) in early treatment, fading as the body adapts. Both carry the FDA boxed warning for thyroid C-cell tumors and contraindications for personal/family history of medullary thyroid carcinoma.
Side-effect rate comparator
Trial-derived adverse-event rates with placebo delta. Sourced from FDA-approved labels for each drug. Most sources omit placebo rates entirely.
| Adverse event | Mounjaro | Zepbound |
|---|---|---|
| Nausea | 18%(placebo 4%) +14.0 pp vs placebo | 28%(placebo 8%) +20.0 pp vs placebo |
| Diarrhea | 17%(placebo 9%) +8.0 pp vs placebo | 23%(placebo 8%) +15.0 pp vs placebo |
| Vomiting | 9%(placebo 2%) +7.0 pp vs placebo | 13%(placebo 2%) +11.0 pp vs placebo |
| Decreased appetite | 11%(placebo 1%) +10.0 pp vs placebo | — |
| Constipation | 7%(placebo 1%) +6.0 pp vs placebo | 11%(placebo 5%) +6.0 pp vs placebo |
| Dyspepsia | 5%(placebo 3%) +2.0 pp vs placebo | 10%(placebo 4%) +6.0 pp vs placebo |
| Abdominal pain | 5%(placebo 4%) +1.0 pp vs placebo | 10%(placebo 5%) +5.0 pp vs placebo |
| Injection-site reactions | — | 8%(placebo 2%) +6.0 pp vs placebo |
| Fatigue | — | 7%(placebo 3%) +4.0 pp vs placebo |
Patients who tolerate one GLP-1 well often (but not always) tolerate another. Switching between class members typically requires re-titration regardless of prior tolerability. See full side-effect breakdowns for Mounjaro and Zepbound.
Dosing schedule comparison
Both medications use step-up titration to minimize side effects, but the schedule details differ:
Mounjaro
- Weeks 1–4: 2.5 mg/week
- Weeks 5–8: 5 mg/week
- Weeks 9–12: 7.5 mg/week
- Weeks 13–16: 10 mg/week
- Weeks 17–20: 12.5 mg/week
- Week 21+: 15 mg/week
Zepbound
- Weeks 1–4: 2.5 mg/week
- Weeks 5–8: 5 mg/week
- Weeks 9–12: 7.5 mg/week
- Weeks 13–16: 10 mg/week
- Weeks 17–20: 12.5 mg/week
- Week 21+: 15 mg/week
See full titration guides for Mounjaro dosing and Zepbound dosing.
Cost comparison
Cost differences between Mounjaro and Zepbound depend on insurance coverage, manufacturer savings programs, and partner-network pricing — not just retail price.
- Average retail price (Mounjaro): $1069/month
- Average retail price (Zepbound): $1086/month
- Mounjaro savings card: as low as $25/month for eligible commercial-insured
- Zepbound savings card: as low as $25/month for eligible commercial-insured
For most patients, the actual out-of-pocket cost is driven by: (1) what your insurance formulary tier places Mounjaro vs Zepbound, (2) whether you qualify for manufacturer savings cards (commercial insurance only), and (3) telehealth partner network availability. Full cost breakdowns: Mounjaro cost guide · Zepbound cost guide.
Which one to choose — decision factors
There's no single «better» drug — the right choice depends on individual circumstances. The key decision factors:
Choose Mounjaro if…
- Your insurance covers it but not Zepbound
- Your prescriber has more experience with it
Choose Zepbound if…
- Your insurance covers it but not Mounjaro
- Your prescriber has more experience with it
Switching from Mounjaro to Zepbound (or vice versa)
Because Mounjaro and Zepbound contain the same active ingredient, switching between them is relatively simple — your prescriber can often transition you at the dose-equivalent point without re-titration. Common reasons to switch include insurance formulary changes, different FDA-approved indications, or different dose ranges (e.g., Wegovy goes higher than Ozempic; Zepbound and Mounjaro have different labeled indications despite identical active ingredient).
FAQ — Mounjaro vs Zepbound
Are Mounjaro and Zepbound the same drug?
Yes — both contain tirzepatide. They differ in FDA-approved indications, dose ranges, and labeling, but the active ingredient is identical.
Which is more effective for weight loss, Mounjaro or Zepbound?
Zepbound produced about 22.5% average weight loss in SURMOUNT-1. Mounjaro has no weight-loss trial of its own to set against it, so the two cannot be ranked on weight loss.
Can I take Mounjaro and Zepbound together?
No. Combining two GLP-1 receptor agonists provides no added benefit and dramatically increases side-effect risk. Standard practice is to switch between them, not combine them.
Which has fewer side effects, Mounjaro or Zepbound?
Both mostly cause stomach side effects. In their labels' placebo-controlled tables, nausea was reported by 18% on Mounjaro (placebo 4%) and 28% on Zepbound (placebo 8%). The trials used different doses and populations, so this is not a head-to-head comparison.
Will my insurance cover Mounjaro but not Zepbound?
Often the coverage differs. Insurance formularies are negotiated separately per drug — Mounjaro may be on Tier 2 of your plan while Zepbound is Tier 4 or excluded. Check your formulary before assuming both are equally accessible.
Editorial comparison based on FDA prescribing information and published clinical data. Not a substitute for prescriber consultation. Full medical disclaimer.